Friday, 20 November 2026European Markets

MEDINCELL Stock Bearish By 27% In The Last 21 Sessions

Automated market report from our archive (2020-2024), published before source-traceability. How we work

Loading stream...

(vianews) - shares of medincell (cac 40: medcl.pa) fell by a staggering 27.27% in 21 sessions from €9.35 to €6.80 at 11:05 est on monday, following the last session's upward trend. cac 40 is falling 0.03% to €7,490.04, after two sequential sessions in a row of gains.

medincell's last close was €6.76, 35.62% below its 52-week high of €10.50.

about medincell

medincell s.a. develops various therapeutic solutions in france. it develops solutions based on bepo, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. the company's products in development include mdc-irm, a risperidone extended-release injectable suspension completed phase iii trial for use in the treatment of schizophrenia; mdc-cwm, a sustained-release formulation of celecoxib in phase iii trials for use in the treatment of reduction of postoperative pain & inflammation; and mdc-tjk, a subcutaneous injection in phase iii trials for use in the treatment of schizophrenia. its product candidates in preclinical trials, such as mdc-ang, an antipsychotic product for use in the treatment of schizophrenia; mdc-ttg for covid-19 and its variants; mdc-grt for use in organ transplant; mdc-wwm for contraception; mdc-stm for use in malaria; mdc-kpt for use in acute pain for pets; and mdc-irm for use in neuroscience. the company was incorporated in 2003 and is based in jacou, france.

earnings per share

as for profitability, medincell has a trailing twelve months eps of €-0.93.

more news about medincell (medcl.pa).

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →

Not a source? Spotted an error? Report an error

How this story was made

Spotted an error? Use “Correct this article” (bottom right), or select any sentence, to report it or respond to that point.

  1. Published before we listed source documents with each article.
  2. Published 22 May 2023
  3. No responses yet from the people or organisations in this story. Are you in this story? Respond on the record ›
  4. Part of the Via News record, fingerprinted daily so it cannot be quietly rewritten. What that means › · Report an error ›